JSPR Jasper Therapeutics, Inc. Stock Quote

JSPR [NASD]

Index	-	P/E	-	EPS (ttm)	-0.34	Insider Own	25.70%	Shs Outstand	12.50M	Perf Week	-30.02%
Market Cap	318.96M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-19.99%
Income	-4.30M	PEG	-	EPS next Q	-	Inst Own	57.10%	Short Float	-	Perf Quarter	15.59%
Sales	-	P/S	-	EPS this Y	-986.70%	Inst Trans	298.97%	Short Ratio	0.04	Perf Half Y	14.90%
Book/sh	6.90	P/B	1.67	EPS next Y	-	ROA	-4.30%	Target Price	-	Perf Year	15.77%
Cash/sh	0.01	P/C	1063.21	EPS next 5Y	-	ROE	-4.80%	52W Range	7.11 - 18.88	Perf YTD	14.79%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-39.14%	Beta	-
Dividend %	-	Quick Ratio	1.30	Sales past 5Y	-	Gross Margin	-	52W Low	61.60%	ATR	2.55
Employees	24	Current Ratio	1.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	50.34	Volatility	14.83% 27.36%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-4.00%	Profit Margin	-	Rel Volume	0.28	Prev Close	13.25
Shortable	No	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	2.69M	Price	11.49
Recom	-	SMA20	2.90%	SMA50	8.88%	SMA200	13.01%	Volume	765,503	Change	-13.28%

Oct-21-21

Initiated

William Blair

Outperform

Oct-20-21

Initiated

BMO Capital Markets

Outperform

$19

Oct-13-21

Initiated

Oppenheimer

Outperform

$21

Oct-15-21 09:39PM

Jasper Therapeutics Stock Is up 127% in Three Days. How Much Higher Can It Go?

TipRanks +31.57%

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience